Research output per year
Research output per year
Personal profile
Research interests
Prevention of tropical diseases in travelers: optimizing vaccination and malaria chemoprophylaxis regimens
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Can haematological changes constitute a surrogate diagnostic parameter to detect schistosomiasis in migrants and travellers? - A retrospective analysis
Schnyder, J. L., Gobbi, F., Schunk, M., Lindner, A., Salvador, F., Duvignaud, A., Arsuaga Vicente, M., Dejon Agobé, J. C., Cattaneo, P., Bertoli, G., Rothe, C., Wintel, M., Pou, D., Malvy, D., Adegnika, A. A., de Jong, H. K. & Grobusch, M. P., 1 Jun 2023, In: New Microbes and New Infections. 53, 101136.Research output: Contribution to journal › Article › Academic › peer-review
Open Access1 Citation (Scopus) -
COVID-19 impact on EuroTravNet infectious diseases sentinel surveillance in Europe
for EuroTravNet, 1 May 2023, In: Travel medicine and infectious disease. 53, 102583.Research output: Contribution to journal › Article › Academic › peer-review
Open Access3 Citations (Scopus) -
On the potential for discontinuing atovaquone-proguanil (AP) ad-hoc post-exposure and other abbreviated AP-regimens: Pharmacology, pharmacokinetics and perspectives
Schnyder, J. L., de Jong, H. K., Bache, E. B., van Hest, R. M., Schlagenhauf, P., Borrmann, S., Hanscheid, T. & Grobusch, M. P., 1 Mar 2023, In: Travel medicine and infectious disease. 52, p. 102520 102520.Research output: Contribution to journal › Article › Academic › peer-review
Open Access1 Citation (Scopus) -
Discontinuing atovaquone/proguanil prophylaxis ad-hoc post-exposure and during-travel dose-sparing prophylactic regimens against P. falciparum malaria: An update with pointers for future research
Schnyder, J. L., de Jong, H. K., Schlagenhauf, P., Borrmann, S., Hanscheid, T. & Grobusch, M. P., 1 Sept 2022, In: Travel medicine and infectious disease. 49, 102365.Research output: Contribution to journal › Review article › Academic › peer-review
Open Access1 Citation (Scopus) -
Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
HERALD Study Group, 1 Mar 2022, In: Lancet infectious diseases. 22, 3, p. 329-340 12 p.Research output: Contribution to journal › Article › Academic › peer-review
Open Access88 Citations (Scopus)